Healthcare / Medical DevicesShanghai
$24.67
-0.50 (-1.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-31.3M · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$11.6B
P/E
189.8x
↑EV/EBITDA
128.9x
↑ROE
2.8%
↑Gross Margin
58.0%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+21.3%
FCF CAGR
—
FCF margin
-6.7%
FCF / Net income
-0.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $464.5M · net income $51.1M · FCF $-31.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $464.5M | $464.5M | $413.2M | $329.2M | $260.3M |
| Net Income | $51.1M | $51.1M | $52.1M | $5.7M | $3.1M |
| EBITDA | $88.0M | $88.0M | $90.4M | $35.7M | $21.0M |
| EPS | 0.11 | 0.11 | 0.11 | 0.01 | 0.01 |
| Gross Margin | 58.0% | 58.0% | 58.7% | 63.5% | 69.1% |
| Operating Margin | 8.4% | 8.4% | 8.6% | -5.7% | -2.4% |
| Net Margin | 11.0% | 11.0% | 12.6% | 1.7% | 1.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 |
| Current Ratio | 9.82 | 9.82 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-31.3M | $-31.3M | $23.5M | $-79.9M | $-41.3M |
| Returns | |||||
| ROE | 2.8% | 2.8% | 3.0% | 0.3% | 0.2% |
| Valuation | |||||
| P/E | 189.77 | 189.77 | 164.92 | 1940.50 | 3657.53 |
| EV/EBITDA | 128.90 | 128.90 | 92.21 | 302.17 | 508.46 |
| P/B | 6.45 | 6.45 | 4.93 | 6.55 | 6.71 |
| Growth & Yield | |||||
| Revenue Growth | 12.4% | 12.4% | 25.5% | 26.5% | — |
| EPS Growth | -1.9% | -1.9% | 814.0% | 65.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
172.2%
EPS terminal req.
$2.19
Spread vs growth
-174.1%
5Y implied EPS CAGR
89.5%
EPS terminal req.
$2.65
Spread vs growth
-91.4%
10Y implied EPS CAGR
44.4%
EPS terminal req.
$4.27
Spread vs growth
-46.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+20.3%
Start / end P/E
185.4x → 227.4x
EPS bridge
0.11 → 0.11
Residual
-0.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.